Verified employee & interview reviews

Bristol Myers Squibb Reviews

New York, New York

4.0/ 5

1 review

Bristol Myers Squibb (BMS), legally known as Bristol-Myers Squibb Company, is a prominent global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines designed to help patients prevail over serious diseases. Headquartered in Princeton, New Jersey, with key corporate operations long rooted in New York City, the multinational corporation stands as a leading force in the brand-name pharmaceutical manufacturing industry, commanding a major market share worldwide. The company was officially formed in 1989 through the high-profile merger of Bristol-Myers Company (founded in 1887 by William McLaren Bristol and John Ripley Myers as the Clinton Pharmaceutical Company) and Squibb Corporation (founded in 1858 by Dr. Edward Robinson Squibb). Throughout its history, BMS shifted from historical, consumer-focused staples like Sal Hepatica laxative salts and Ipana toothpaste to a specialized focus on prescription biopharmaceuticals. Today, the company centers its scientific research and commercial operations around five core therapeutic areas: oncology, hematology, immunology, cardiovascular disease, and neuroscience. BMS maintains a powerful portfolio of blockbuster drugs and commercial therapies that drive its substantial annual revenue, which reached approximately $48.48 billion for the trailing twelve months leading into 2026. Major revenue-generating products include apixaban (Eliquis), an oral anticoagulant used to reduce the risk of stroke in patients with atrial fibrillation; nivolumab (Opdivo), a highly successful immunotherapy utilized in treating various cancers; and abatacept (Orencia), prescribed for autoimmune conditions like rheumatoid arthritis. The company has actively navigated patent cliffs on legacy blockbuster drugs by executing aggressive acquisitions to bolster its future pipeline. Notable strategic expansions include the $74 billion acquisition of Celgene in 2019, the purchase of Turning Point Therapeutics in 2022, and a multi-billion-dollar wave of acquisitions in 2024 including RayzeBio, Mirati Therapeutics, and Karuna Therapeutics. The latter brought the pioneering schizophrenia drug KarXT (Cobenfy) into its portfolio, marking a historical milestone in psychiatric treatment. Led by Chief Executive Officer Dr. Christopher S. Boerner, BMS employs an estimated 32,500 people globally. The company operates a vast network of advanced research and development infrastructure spanning across domestic facilities in New Jersey, California, and Massachusetts, alongside major international R&D hubs in Spain, Belgium, Japan, the United Kingdom, and India (including specialized centers in Hyderabad and Bangalore). Beyond commercial and scientific ventures, the company drives community and global health equity initiatives via the Bristol Myers Squibb Foundation, which supports expansive oncology, HIV/AIDS, and basic human services programs across underserved regions worldwide.